Compare IDT & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDT | BBOT |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | N/A | N/A |
| Metric | IDT | BBOT |
|---|---|---|
| Price | $48.30 | $8.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.00 |
| AVG Volume (30 Days) | 129.8K | ★ 184.8K |
| Earning Date | 03-10-2026 | 03-05-2026 |
| Dividend Yield | ★ 0.59% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.99 | N/A |
| Revenue Next Year | $1.51 | N/A |
| P/E Ratio | $15.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $45.35 | $8.67 |
| 52 Week High | $71.12 | $14.87 |
| Indicator | IDT | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 45.03 | 37.36 |
| Support Level | $46.84 | $8.80 |
| Resistance Level | $51.62 | $12.36 |
| Average True Range (ATR) | 1.56 | 0.58 |
| MACD | -0.34 | -0.05 |
| Stochastic Oscillator | 24.27 | 10.95 |
IDT Corp is a multinational holding company. It operates in the telecommunications and payment industries. It has four reportable business segments, Fintech, National Retail Solutions; net2phone and Traditional Communications, The Fintech segment is comprised of National Retail Solutions (NRS), an operator of a nationwide point of sale (POS) network providing payment processing, digital advertising, transaction data, and ancillary services, and BOSS Money, a provider of international money remittance and related value/payment transfer services. The net2phone segment provides unified cloud communications and telephony services to business customers.
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.